BioSpace – Frequency Therapeutics Completes $62 Million Series C Financing

Frequency Therapeutics, a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the closing of a $62.0 million Series C financing. Frequency will use the proceeds to support the clinical development of FX-322, a regenerative therapeutic for the treatment of sensorineural hearing loss that is moving into a Phase 2a study, and to advance discovery programs in other therapeutic areas using its proprietary Progenitor Cell Activation (PCA) platform.

Continue reading on BioSpace

By Danielle Grassia Canas (on leave Summer 2022)
Danielle Grassia Canas (on leave Summer 2022) Senior Associate Director, Recruiting Operations